Publicaciones en colaboración con investigadores/as de Stanford University School of Medicine (73)

2024

  1. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  2. GeNNius: an ultrafast drug-target interaction inference method based on graph neural networks

    Bioinformatics (Oxford, England), Vol. 40, Núm. 1

  3. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  4. MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

    Nature Genetics

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 2, pp. 328-343

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Identifying key multifunctional components shared by critical cancer and normal liver pathways via SparseGMM

    Cell Reports Methods, Vol. 3, Núm. 1

  5. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  6. Long non-coding RNAs: definitions, functions, challenges and recommendations

    Nature Reviews Molecular Cell Biology, Vol. 24, Núm. 6, pp. 430-447

  7. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Approach to Lower Urinary Tract Reconstruction: A Survey of Adult and Pediatric Urologist Perspectives and Experiences

    Frontiers in Urology, Vol. 2

  2. Genomic profiling for clinical decision making in lymphoid neoplasms

    Blood

  3. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

    Nature Immunology, Vol. 23, Núm. 10, pp. 1495-1506

  4. Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 65-122

  5. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

  6. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

  7. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Elevated NSD3 histone methylation activity drives squamous cell lung cancer

    Nature, Vol. 590, Núm. 7846, pp. 504-508

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382